As one of business areas within Actelion Pharmaceuticals Deutschland GmbH we are offeringdiversified Pharmaceutical CDMO and biotechnology contract development and manufacturing expertise, ranging from mammalian cell cultures to microbial and yeast fermentations to the pharmaceutical and biotechnology industry.As a part of the renowned Actelion Pharmaceuticals Deutschland, CDMO division offers comprehensivediversified Pharmaceutical CDMO and biotechnology services. They specialize in the development and manufacturing of biologics, including monoclonal antibodies, recombinant proteins, and biosimilars. With a global presence and cutting-edge facilities, they provide end-to-end solutions from cell line development to commercial manufacturing.
As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease. H3 K27M-mutant diffuse midline glioma is a highly aggressive brain tumor most commonly found in children and young adults. Because of poor prognosis associated with this disease due to its deep location in the brain and aggressive biology, early identification and accurate molecular diagnosis are essential to help determine the best treatment course. Scientific advances are reshaping how small cell lung cancer is understood and treated. As interest grows in first-line maintenance strategies, researchers are exploring new ways to extend the impact of initial therapy in this historically difficult-to-treat cancer.